Full Text
EE652 Cost Effectiveness Analysis of Pembrolizumab for the Treatment of Advanced or Metastatic Renal Cell Carcinoma

Abstract

Authors

N Yfantopoulos I Bafaloukos I Dimitriadis A Skroumpelos A Karokis

Back to Volume 25, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×